A balanced analysis of the trade-offs between building an in-house medical writing function and partnering with a specialist provider — covering cost, quality control, flexibility, and regulatory risk. Includes a framework for evaluating which model suits different stages of a biotech company’s growth. Targeted at VP-level regulatory and clinical development leaders at emerging biotech organisations.
